XML 56 R46.htm IDEA: XBRL DOCUMENT v3.22.2
COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($)
 6 Months Ended 12 Months Ended
Feb. 28, 2022
Dec. 10, 2021
Dec. 10, 2021
Jun. 30, 2022
Dec. 31, 2018
Dec. 31, 2016
Dec. 31, 2021
Loss Contingencies [Line Items]              
Purchase obligation       $ 1,900,000     $ 511,000
Stockholders' equity, reverse stock split     5-for-1        
Maximum [Member]              
Loss Contingencies [Line Items]              
Proceeds from issuance of common stock       $ 150,000,000      
Harborside [Member]              
Loss Contingencies [Line Items]              
Stock issued during period, shares, reverse stock splits     1,000,000        
Stock issued during period, shares, stock splits     200,000        
Revenue     $ 10,000,000        
Shares issued   1,000,000 1,000,000        
Incurred damage related aforementioned stock   $ 75,000 $ 75,000        
Harborside [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Loss contingency, damages sought, value     33,020,000        
Harborside [Member] | Minimum [Member]              
Loss Contingencies [Line Items]              
Loss contingency, damages sought, value     $ 5,020,000        
Conversion Labs Rx Business [Member]              
Loss Contingencies [Line Items]              
Stock issued during period, shares, stock splits     200,000        
Conversion Labs Rx Business [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Stock issued during period, shares, stock splits     1,000,000        
Pilaris Laboratories LLC [Member]              
Loss Contingencies [Line Items]              
Finite-lived intangible asset, useful life           10 years  
Percentage of net income           10.00%  
Share based compensation arrangement by share based payment award, expiration period         10 years    
Pilaris Laboratories LLC [Member] | CVLB PR [Member]              
Loss Contingencies [Line Items]              
Agreements of performance fees, description           As consideration for granting Conversion Labs PR this license, Pilaris will receive on quarterly basis, 10% of the net income collected by the licensed products based on the following formula: Net Income = total income – cost of goods sold – advertising and operating expenses directly related to the marketing of the licensed products.  
MALPHABET LLC [Member]              
Loss Contingencies [Line Items]              
Agreements of performance fees, description       The Company shall pay Alphabet a royalty equal to 13% of Gross Receipts (as defined in the Agreement) realized from the sales of Licensed Products. No amounts were earned or owed as of June 30, 2022.      
Percentage for royalty       13.00%      
Share based compensation arrangement by share based payment award, options, grants in period, gross         20,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price         $ 2.50    
MALPHABET LLC [Member] | Common Stock One [Member]              
Loss Contingencies [Line Items]              
Share based compensation arrangement by share based payment award, options, grants in period, gross         20,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price         $ 2.50    
Proceeds from issuance of common stock         $ 7,500,000    
MALPHABET LLC [Member] | Common Stock Two [Member]              
Loss Contingencies [Line Items]              
Share based compensation arrangement by share based payment award, options, grants in period, gross         20,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price         $ 2.50    
Proceeds from issuance of common stock         $ 10,000,000    
MALPHABET LLC [Member] | Common Stock Three [Member]              
Loss Contingencies [Line Items]              
Share based compensation arrangement by share based payment award, options, grants in period, gross         40,000    
Share based compensation arrangements by share based payment award, options, exercises in period, weighted average exercise price         $ 3.75    
Proceeds from issuance of common stock         $ 20,000,000    
Conversion Labs Rx Business [Member] | Harborside [Member]              
Loss Contingencies [Line Items]              
Adjustments to additional paid in capital, stock issued, issuance costs     $ 5,000,000        
Conversion Labs Rx Business [Member] | Harborside [Member] | Maximum [Member]              
Loss Contingencies [Line Items]              
Adjustments to additional paid in capital, stock issued, issuance costs     $ 5,000,000        
Conversion Labs Rx [Member]              
Loss Contingencies [Line Items]              
[custom:LossContingencyBreachOfContractAmount]   $ 273,859          
Blair LLC [Member]              
Loss Contingencies [Line Items]              
[custom:LossContingencyBreachOfContractAmount] $ 1,000,000